SEC Form 4 · accession 0001562180-15-000557

Sage Therapeutics, Inc. · SAGE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 1, 2015

Accepted (ET)

Jul 2, 2015 · 2:10 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001597553

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Jul 1, 2015	S	700	$72.44	D	742,950	D
Common Stock^F3	Jul 1, 2015	S	5,336	$71.47	D	737,614	D
Common Stock^F4	Jul 1, 2015	S	1,600	$70.50	D	736,014	D
Common Stock^F5	Jul 1, 2015	S	1,859	$68.90	D	734,155	D
Common Stock^F6	Jul 1, 2015	S	9,702	$68.12	D	724,453	D
Common Stock^F7	Jul 1, 2015	S	803	$67.46	D	723,650	D

No Table II lines on this filing.

F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2This transaction was executed in multiple trades at prices ranging from $72.01 USD to $73.01 USD. The price reported above reflects the weighted average sale price.
F3This transaction was executed in multiple trades at prices ranging from $71.02 USD to $71.89 USD. The price reported above reflects the weighted average sale price.
F4This transaction was executed in multiple trades at prices ranging from $70.01 USD to $70.81 USD. The price reported above reflects the weighted average sale price.
F5This transaction was executed in multiple trades at prices ranging from $68.59 USD to $69.57 USD. The price reported above reflects the weighted average sale price.
F6This transaction was executed in multiple trades at prices ranging from $67.56 USD to $68.56 USD. The price reported above reflects the weighted average sale price.
F7This transaction was executed in multiple trades at prices ranging from $67.38 USD to $67.55 USD. The price reported above reflects the weighted average sale price.